ImmunityBio
IBRX
IBRX
116 hedge funds and large institutions have $109M invested in ImmunityBio in 2023 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 50 increasing their positions, 23 reducing their positions, and 44 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
20% less funds holding
Funds holding: 145 → 116 (-29)
64% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 44
Holders
116
Holding in Top 10
–
Calls
$10.5M
Puts
$8.69M
Top Buyers
| 1 | +$7.04M | |
| 2 | +$5.69M | |
| 3 | +$2.18M | |
| 4 |
National Bank of Canada
Montreal,
Quebec, Canada
|
+$1.82M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$973K |
Top Sellers
| 1 | -$10.5M | |
| 2 | -$6.67M | |
| 3 | -$5.07M | |
| 4 |
SSWM
Sheets Smith Wealth Management
Winston-Salem,
North Carolina
|
-$3.67M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.99M |